Is Enzolytics IPF Immune Pushing ENZC Stock To New Highs in February?

A month ago Enzolytics has shown its plans to commercialize its immune backing medicine Enzolytics IPF Immune as the healthcare market is demanding endless immune-protecting drugs to confront any covid-19 variants.

The Texas-based company’s CEO Charles S. Cotropia has proudly said, “Enzolytics IPF Immune™ is the supplement for the post-pandemic era. Immunity booster supplements have become very popular because of COVID-19, and we believe consumers will choose our supplement because our immune modulator helps fortify the immune system against infections.”

Right now it is clear that ENZC shares are experiencing a bullish trend on year to date basis. Therefore, spending a couple of hundreds of US dollars might boost your biotech portfolio earnings this year.